imiquimod has been researched along with Bladder Cancer in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arimura, A; Kanekura, T; Kirishima, M; Tanimoto, A | 1 |
| Belkoff, LH; Belldegrun, AS; Chamie, K; Donin, NM; Hakim, G; Holden, S; Holldack, J; Karsh, LI; Kivlin, D; Lamm, DL; Lenis, AT; Pantuck, AJ; Pozzi, R; Reddy, M; Shore, N | 1 |
| Billis, A; Camargo, JA; Ferrari, KL; Passos, GR; Reis, LO; Saad, MJA | 1 |
| Falke, J; Hulsbergen-van de Kaa, CA; Maj, R; Oosterwijk, E; Witjes, JA | 1 |
| Innamaa, A; Lippiatt, J; Melson, L; Mujukian, A | 1 |
| Barberis, A; Carson, DA; Chan, M; Corr, M; Cottam, HB; Crain, B; Hayashi, T; Leoni, L; Maj, R | 1 |
| Olbert, PJ | 1 |
| Arum, CJ | 1 |
| Arentsen, HC; Cornel, EB; de Reijke, TM; Falke, J; Lammers, RJ; Pozzi, R; Ravic, M; Vergunst, H; Witjes, JA | 1 |
| Hwang, D; Kawamoto, H; Liu, H; Scherr, DS; Schwartz, M; Smith, EB; You, X | 1 |
2 trial(s) available for imiquimod and Bladder Cancer
| Article | Year |
|---|---|
A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma in Situ; Cytokines; Fatigue; Female; Humans; Imiquimod; Male; Middle Aged; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with nonmuscle invasive bladder cancer.
Topics: Administration, Intravesical; Adult; Age Factors; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Carcinoma, Transitional Cell; Cystoscopy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imiquimod; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Patient Safety; Prospective Studies; Risk Assessment; Sex Factors; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
8 other study(ies) available for imiquimod and Bladder Cancer
| Article | Year |
|---|---|
Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Female; Humans; Imiquimod; Lung Neoplasms; Neoplasms, Second Primary; Skin Neoplasms; Urinary Bladder Neoplasms | 2019 |
Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; BCG Vaccine; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Imiquimod; Methylnitrosourea; Random Allocation; Rats; Rats, Inbred F344; Ribosomal Protein S6 Kinases, 70-kDa; Toll-Like Receptor 2; Toll-Like Receptor 4; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |
A placebo-controlled efficacy study of the intravesical immunomodulators TMX-101 and TMX-202 in an orthotopic bladder cancer rat model.
Topics: Adenine; Adjuvants, Immunologic; Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Disease Models, Animal; Glycerophospholipids; Imiquimod; Immunologic Factors; Rats; Rats, Inbred F344; Toll-Like Receptor 7; Urinary Bladder; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Extensive extramammary Paget's disease of the vulva involving the bladder postradical split skin graft reconstruction.
Topics: Aged, 80 and over; Antineoplastic Agents; Cystoscopy; Female; Gynecologic Surgical Procedures; Humans; Imiquimod; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Paget Disease, Extramammary; Skin Transplantation; Urethral Neoplasms; Urinary Bladder Neoplasms; Vulvar Neoplasms | 2019 |
Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Adjuvants, Immunologic; Administration, Intravesical; Aminoquinolines; Animals; beta-Cyclodextrins; Chemistry, Pharmaceutical; Cystitis; Cytokines; Disease Models, Animal; Excipients; Female; Imiquimod; Lactic Acid; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Polyethylenes; Polypropylenes; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2010 |
Editorial comment from Dr Olbert to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Imiquimod; Membrane Glycoproteins; Mice; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2010 |
Editorial comment from Dr Arum to Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Chemistry, Pharmaceutical; Disease Models, Animal; Imiquimod; Membrane Glycoproteins; Mice; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2010 |
Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Apoptosis; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cytokines; Disease Models, Animal; Humans; Imiquimod; Mice; Toll-Like Receptor 7; Urinary Bladder Neoplasms | 2007 |